Company Jaguar Health, Inc.

JAGX

US47010C8881

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 19/07/2025 am IST			5-day change	1st Jan Change
2.320 ^USD	0.00%		-14.07%	-90.81%

25/06	Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment	MT
11/06	Jaguar Health Establishes First Site for Canalevia-CA1 Field Study	MT

Business description: Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Number of employees: 49

Sales by Activity: Jaguar Health, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Human Health	93.09L	42.73L	1.17Cr	95.88L	1.14Cr
Animal Health	76T	62T	2L	2L	3L

See all business segments

Executive Committee: Jaguar Health, Inc.

Manager	Title	Age	Since
Lisa Conte CEO	Chief Executive Officer	66	06/06/2013
Carol Lizak DFI	Director of Finance/CFO	61	13/08/2019
Darlene P. Horton CTO	Chief Tech/Sci/R&D Officer	63	01/05/2021
Jonathan Wolin CMP	Compliance Officer	63	01/11/2018
Pravin Ramsewak Chaturvedi CTO	Chief Tech/Sci/R&D Officer	62	01/03/2022

See JAGUAR HEALTH, INC. governance

Composition of the Board of Directors: Jaguar Health, Inc.

Director	Title	Age	Since
Lisa Conte BRD	Director/Board Member	66	06/06/2013
James Bochnowski CHM	Chairman	81	01/06/2014
John Micek BRD	Director/Board Member	72	01/04/2016
Jonathan Siegel BRD	Director/Board Member	51	29/03/2018
Anula Kusum Jayasuriya BRD	Director/Board Member	68	01/07/2022

Composition of the Board of Directors

Shareholders: Jaguar Health, Inc.

Name	Equities	%	Valuation
Heights Capital Management, Inc. 7.846 %	1,03,912	7.846 %	261 858 $
Intracoastal Capital LLC 4.908 %	65,002	4.908 %	163 805 $
Fredrick Waid 3.857 %	51,084	3.857 %	128 732 $
Streeterville Management LLC 3.434 %	45,478	3.434 %	114 605 $
Iliad Management Ltd. 2.403 %	31,830	2.403 %	80 212 $

List of JAGUAR HEALTH, INC. shareholders

Company details: Jaguar Health, Inc.

Jaguar Health, Inc.

200 Pine Street Suite 400

94104, San Francisco

http://www.jaguar.health

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
JAGUAR HEALTH, INC.	0.00%	-14.07%	-97.70%	-99.99%	30.73L
ELI LILLY AND COMPANY	+1.34%	-2.69%	-9.09%	+139.83%	69TCr
JOHNSON & JOHNSON	+0.44%	+4.33%	+5.33%	-6.04%	39TCr
ABBVIE INC.	-1.12%	-1.66%	+10.59%	+26.54%	33TCr
NOVO NORDISK A/S	-2.22%	-5.55%	-53.26%	-1.90%	29TCr
ROCHE HOLDING AG	+0.58%	+0.66%	-7.15%	-21.43%	26TCr
NOVARTIS AG	-1.12%	-4.09%	-2.94%	+12.40%	22TCr
ASTRAZENECA PLC	-0.17%	-1.49%	-15.11%	-7.23%	21TCr
MERCK & CO., INC.	-1.91%	-4.08%	-35.65%	-13.41%	20TCr
AMGEN INC.	-1.17%	-0.17%	-10.94%	+20.88%	16TCr
Average	-0.46%	-2.98%	-21.59%	+4.96%	27.65TCr
Weighted average by Cap.	-0.41%	-1.66%	-11.07%	+35.84%